JP2017529386A - 癌治療に有用なペプチド - Google Patents

癌治療に有用なペプチド Download PDF

Info

Publication number
JP2017529386A
JP2017529386A JP2017526762A JP2017526762A JP2017529386A JP 2017529386 A JP2017529386 A JP 2017529386A JP 2017526762 A JP2017526762 A JP 2017526762A JP 2017526762 A JP2017526762 A JP 2017526762A JP 2017529386 A JP2017529386 A JP 2017529386A
Authority
JP
Japan
Prior art keywords
pro
compound
arg
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017526762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529386A5 (enExample
Inventor
ヒルマー エム． ワレニウス
ヒルマー エム． ワレニウス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2017529386A publication Critical patent/JP2017529386A/ja
Publication of JP2017529386A5 publication Critical patent/JP2017529386A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
JP2017526762A 2014-08-06 2015-08-05 癌治療に有用なペプチド Pending JP2017529386A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1413942.2A GB2530479A (en) 2014-08-06 2014-08-06 Peptides useful for treating cancer
GB1413942.2 2014-08-06
PCT/EP2015/068056 WO2016020437A1 (en) 2014-08-06 2015-08-05 Peptides useful for treating cancer

Publications (2)

Publication Number Publication Date
JP2017529386A true JP2017529386A (ja) 2017-10-05
JP2017529386A5 JP2017529386A5 (enExample) 2018-09-20

Family

ID=51587828

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526762A Pending JP2017529386A (ja) 2014-08-06 2015-08-05 癌治療に有用なペプチド

Country Status (9)

Country Link
US (1) US20170313746A1 (enExample)
EP (1) EP3177716A1 (enExample)
JP (1) JP2017529386A (enExample)
CN (1) CN107406485A (enExample)
AU (1) AU2015299032A1 (enExample)
CA (1) CA2960070A1 (enExample)
GB (1) GB2530479A (enExample)
RU (1) RU2017106945A (enExample)
WO (1) WO2016020437A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
GB201602409D0 (en) * 2016-02-10 2016-03-23 Warenius Hilmar M Compositions and uses thereof
GB2582571B (en) 2019-03-25 2024-02-28 Syntherix Ltd Peptides and use thereof
CN113109418B (zh) * 2021-04-21 2022-09-09 苏州大学 一种己糖激酶2抑制剂的筛选方法和小分子化合物在制备抗肿瘤药物中的应用
GB2628421A (en) 2023-03-24 2024-09-25 Syntherix Ltd Peptides and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002045720A1 (en) * 2000-12-04 2002-06-13 Sloan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
US20050003546A1 (en) * 2001-07-05 2005-01-06 Yale University Viral uptake into cells and tissues
WO2009112536A1 (en) * 2008-03-11 2009-09-17 Theryte Limited Treating cancer
WO2014004935A2 (en) * 2012-06-27 2014-01-03 Siscapa Assay Technologies, Inc. Multipurpose mass spectrometric assay panels for peptides
WO2014053879A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014055836A2 (en) * 2012-10-04 2014-04-10 Research Development Foundation Serine protease molecules and therapies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439031B2 (en) * 2003-12-15 2008-10-21 The Trustees Of The University Of Pennsylvania Method of identifying compounds that induce cell death by necrosis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002045720A1 (en) * 2000-12-04 2002-06-13 Sloan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
US20050003546A1 (en) * 2001-07-05 2005-01-06 Yale University Viral uptake into cells and tissues
WO2009112536A1 (en) * 2008-03-11 2009-09-17 Theryte Limited Treating cancer
WO2014004935A2 (en) * 2012-06-27 2014-01-03 Siscapa Assay Technologies, Inc. Multipurpose mass spectrometric assay panels for peptides
WO2014053879A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014055836A2 (en) * 2012-10-04 2014-04-10 Research Development Foundation Serine protease molecules and therapies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOL. PHARM., vol. 10, no. 5, JPN6019026113, 28 March 2013 (2013-03-28), pages 2008 - 2020, ISSN: 0004070625 *
MOLECULAR CANCER, vol. 10, no. 72, JPN6019026115, 2011, pages 1 - 16, ISSN: 0004070626 *
TRENDS IN CELL BIOLOGY, vol. 8, JPN6019026111, February 1998 (1998-02-01), pages 84 - 87, ISSN: 0004070624 *

Also Published As

Publication number Publication date
AU2015299032A1 (en) 2017-03-23
US20170313746A1 (en) 2017-11-02
RU2017106945A3 (enExample) 2019-03-28
CN107406485A (zh) 2017-11-28
EP3177716A1 (en) 2017-06-14
RU2017106945A (ru) 2018-09-06
GB201413942D0 (en) 2014-09-17
GB2530479A (en) 2016-03-30
CA2960070A1 (en) 2016-02-11
WO2016020437A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
Kaur et al. Role of p53 gene in breast cancer: focus on mutation spectrum and therapeutic strategies
Testa et al. Deregulation of apoptosis in acute myeloid leukemia
An et al. Tanshinone IIA activates nuclear factor-erythroid 2-related factor 2 to restrain pulmonary fibrosis via regulation of redox homeostasis and glutaminolysis
Islam et al. The oncogenic role of ubiquitin specific peptidase (USP8) and its signaling pathways targeting for cancer therapeutics
JP2017529386A (ja) 癌治療に有用なペプチド
JP2011504462A (ja) 腫瘍の予防および治療のための方法および化合物
E. Griguer et al. Bioenergetics pathways and therapeutic resistance in gliomas: emerging role of mitochondria
Mendoza et al. Anti-tumor chemotherapy utilizing peptide-based approaches-apoptotic pathways, kinases, and proteasome as targets
D’Amelio et al. The apoptosome: emerging insights and new potential targets for drug design
CA2866020A1 (en) Procaspase combination therapy for glioblastoma
WO2017189856A2 (en) Compositions and methods for treating cancer
EP2160196A2 (en) Compounds for the treatment of ischemia and neurodegeneration
Patel et al. Novel cell-penetrating peptide conjugated proteasome inhibitors: anticancer and antifungal investigations
Nozaki et al. Borealin-derived peptides as survivin-targeting cancer imaging and therapeutic agents
Pérez‐Payá et al. Molecules that modulate Apaf‐1 activity
Griffith et al. Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist
EP3947418B1 (en) Peptides and use thereof
US20190046600A1 (en) Compositions and uses thereof
US10793601B2 (en) Therapeutic spalt-like transcription factor 4 (SALL4) peptide
Li Gelatinase inhibitors: a patent review (2011-2017)
KR20250036992A (ko) Pld1 활성을 억제하는 항암 펩타이드를 포함하는 암세포 증식 억제용 조성물 및 약학 조성물
Chen et al. Further structural optimization and SAR study of sungsanpin derivatives as cell-invasion inhibitors
Valter Mitochondria targeting and its consequences for cell death in neuroblastoma
Ditsworth et al. Therapeutic Approaches to Modulation of Cell Death (non-HIV)
CA3196140A1 (en) Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200108